Form 8-K

8-K — MYOMO, INC.

Accession: 0001193125-26-335109

Filed: 2026-08-05

Period: 2026-08-05

CIK: 0001369290

SIC: 3842 (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — myo-20260805.htm (Primary)

EX-99.1 (myo-ex99_1.htm)

GRAPHIC (img133186882_0.gif)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: myo-20260805.htm · Sequence: 1

8-K

0001369290false00013692902026-08-052026-08-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2026

Myomo, Inc.

(Exact Name of Company as Specified in Charter)

Delaware

001-38109

47-0944526

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

45 Blue Sky Dr., Suite 101

Burlington, MA

01803

(Address of Principal Executive Offices)

(Zip Code)

Company’s telephone number, including area code: (617) 996-9058

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share

MYO

NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On August 5, 2026, Myomo, Inc, (the "Company") announced its financial results for the second quarter ended June 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01.

(d) Exhibits

Exhibit

No.

Description

99.1

Press release issued by Myomo, Inc. on August 5, 2026, furnished herewith.

104

The cover page from the Company’s Form 8-K dated August 5, 2026, formatted in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MYOMO, INC.

Date:

August 5, 2026

By:

/s/ David A. Henry

David A. Henry

Chief Financial Officer

EX-99.1

Filename: myo-ex99_1.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Myomo Reports Second Quarter 2026 Financial and Operating Results

Revenue of $11.7 million, increased 21% year over year

Four success pillars driving higher revenue growth and operating leverage

Raising full year revenue guidance to $45-47 million

Conference call begins at 4:30pm Eastern time today

BURLINGTON, Mass. (August 5, 2026) – Myomo, Inc. (NYSE American: MYO)(“Myomo” or the “Company”), a wearable medical robotics platform company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three and six months ended June 30, 2026.

“I am pleased to report that the evolution of our go-to-market approach is driving positive results. Revenue of $11.7 million exceeded our expectations, with 53% of second quarter revenues generated from referral network sources through our MyoConnect program and other sales channels. In addition, we generated operating leverage as we grew revenue 21% while holding operating expenses roughly flat," said Paul R. Gudonis, Chairman and Chief Executive Officer of Myomo. “We believe our growing clinical referral network and the increased market awareness of our wearable robotics platform will lead to greater adoption by rehab clinicians and the hundreds of thousands of potential MyoPro candidates they treat. We anticipate continued progress on these initiatives and as a result are raising the revenue guidance to approximately 10-15% growth over the prior year.”

Success Pillar Accomplishments:

•

Shift to Recurring Patient Sources: 53% of second quarter revenue was derived from recurring patient sources, such as provider referrals, orthotic and prosthetic (O&P) partners and the Department of Veteran’s Affairs (VA), up from 26% in the second quarter of 2025. Revenue from the U.S. O&P and International sales channels increased by 130% and 32%, respectively, year-over-year.

•

Increase Market Access with Additional Payer Contracts: Additional state contracts were completed in the second quarter under our multi-state arrangement with Elevance's Anthem Blue Cross Blue Shield Network, with contracts in process with other payers. Including Medicare and VA patients, we have in-network access to more than 100 million covered lives.

•

Demonstrate Operating Leverage: Revenues increased 21% year-over-year, while operating expenses increased less than 1%. In addition, gross margin expanded by 940 basis points year-over year, contributing to a 79% year-over-year improvement in Adjusted EBITDA.

•

Invest in Product Development and Clinical Research: The randomized controlled trial underway at the University of Utah has enrolled 25 of a planned 50 subjects. In addition, MypPro3 development continues to make progress, and we introduced a prototype of a hand-only version for the German market at OT World in May as the next product built upon our mobility robotics platform.

Results of Key Operating Metrics:

•

Added 739 patients to the pipeline in the second quarter, including a 40% sequential increase in pipeline additions from the MyoConnect program.

•

Expanded in-network access and higher quality patient referrals improved order rates, resulting in a record 255 orders in the second quarter, an increase of 23% year over year.

•

Average selling price (“ASP”) was approximately $55,500, up 2% vs. the prior year.

Financial Results

For the Three Months

Ended June 30,

Period-

to-Period

Change

For the Six Months

Ended June 30,

Period-

to-Period

Change

2026

2025

2026

2025

Revenue

11,704,565

9,652,234

2,052,331

21,817,853

19,484,048

2,333,805

Cost of revenue

3,262,017

3,600,061

(338,044

)

6,473,698

6,822,246

(348,548

)

Gross profit

8,442,548

6,052,173

2,390,375

15,344,155

12,661,802

2,682,353

Gross margin %

72.1

62.7

9.4

70.3

65.0

5.3

Revenue: Revenue for the second quarter of 2026 was $11.7 million, up 21% compared with the second quarter of 2025, reflecting a higher ASP, and an increase in the number of revenue units. Myomo recognized revenue on 211 MyoPro units in the quarter, up 19% over the same period a year ago and driven by higher volume in our Direct Billing and O&P sales channels.

Gross Margin: Gross margin for the second quarter of 2026 was 72.1%, compared with 62.7% for the second quarter of 2025. The increase was driven primarily by the higher ASP and the impact of cost reductions, such as the rollout of the Myomo Mobile App which reduces material costs, partially offset by higher clinical costs classified to cost of goods sold.

Operating Expenses: Operating expenses for the second quarter of 2026 were $10.7 million, an increase of less than 1% compared with the second quarter of 2025. The increase was primarily due to higher general and administrative expenses, driven by seasonally higher legal expense, partially offset by lower research and development expenses and lower advertising expense.

Operating and Net Loss: Operating loss for the second quarter of 2026 was $2.3 million, compared with an operating loss of $4.6 million for the second quarter of 2025. Net loss, including a non-cash charge of $1.2 million for the mark-to-market of our derivative liabilities, was $4.0 million, or $0.09 per share for the second quarter of 2026, compared with $4.6 million, or $0.11 per share, for the second quarter of 2025.

Adjusted EBITDA: Adjusted EBITDA loss for the second quarter of 2026 was $0.8 million, compared with $4.0 million for the second quarter of 2025, an improvement of approximately 79%. A reconciliation of GAAP net loss to this non-GAAP financial measure appears below.

Cash, Cash Equivalents and Cash Flows: Cash, cash equivalents and short-term investments as of June 30, 2026, were $13.5 million. Cash used in operating activities was $1.9 million for the second quarter of 2026, compared with $8.9 million used in operating activities in the second quarter of 2025.

Business Outlook

"In the third quarter of 2026, we expect continued year-over-year revenue growth with modestly higher operating expenses on a sequential basis, as we expand our MyoConnect program. We expect third quarter 2026 revenue to be in the range of $11.5 million to $12.0 million, up 14% to 19% year-over-year. We are raising our full year revenue guidance to $45 million to $47 million. We reiterate our full year operating leverage expectation, and we expect cash burn to be less than $2 million during the second half of the year," added Mr. Gudonis.

Conference Call and Webcast

Myomo will hold a conference call today at 4:30 p.m. Eastern time to discuss these results and answer questions. Participants are encouraged to pre-register for the call at this link. Callers who pre-register will receive a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time up to and after the start of the call. Those unable to pre-register may participate by dialing 844-707-6932 (U.S.) or 412-317-9250 (International). A webcast of the call will also be available at Myomo’s Investor Relations page at http://ir.myomo.com/.

A replay of the webcast will be available beginning approximately one hour after the completion of the live conference call at http://ir.myomo.com/. A dial-in replay of the call will be available until August 19, 2026 at 855-669-9658 (U.S./Canada toll-free) or 412-317-0088 (International), with passcode 1135727.

Non-GAAP Financial Measures

Myomo is providing financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. This information includes Adjusted EBITDA. This non-GAAP financial measure is not in accordance with, or an alternative for, GAAP and may be different from similar non-GAAP financial measures used by other companies. Myomo believes the use of this non-GAAP financial measure provides supplementary information for investors to use in evaluating operating performance and in comparing Myomo’s financial measures with other companies in its industry, many of which present similar non-GAAP financial measures. Adjusted EBITDA is EBITDA adjusted for stock-based compensation expense. This non-GAAP financial measure is not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP, and should be viewed in conjunction with GAAP financial measures. Investors are encouraged to review the reconciliation of this non-GAAP measure to its most directly comparable GAAP financial measure. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables included as part of this press release.

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. It is currently the only marketed device in the U.S. that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Burlington, Massachusetts, with sales and clinical professionals across the U.S. and representatives internationally. For more information, please visit www.myomo.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding the Company’s future business expectations, including expectations for second quarter and full year 2026 revenue, and operating leverage expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors.

These factors include, among other things:

•

our ability to obtain sufficient reimbursement from third-party payers for our products;

•

our dependence on external sources for the financing of our operations;

•

our ability to scale the business to achieve positive cash flow from operations;

•

our revenue concentration with patients who carry Medicare Part B;

•

our ability to continue normal operations and patient interactions without supply chain disruption in order to deliver and fit our custom-fabricated devices;

•

our marketing and commercialization efforts;

•

our ability to obtain and maintain our strategic collaborations and to realize the intended results of such collaborations;

•

our expectations as to our product development programs, including improving our existing products and developing new products;

•

our ability to maintain and grow our reputation and to achieve and maintain the market acceptance of our products;

•

our expectations as to our clinical research program and clinical results;

•

our ability to maintain adequate protection of our intellectual property and to avoid violation of the intellectual property rights of others;

•

our ability to gain and maintain regulatory approvals;

•

our ability to compete and succeed in a highly competitive and evolving industry; and

•

general market, economic, environmental and social factors that may affect the evaluation, fitting, delivery and sale of our products to patients.

More information about these and other factors that potentially could affect our financial results is included in Myomo’s filings with the Securities and Exchange Commission, including those contained in the risk factors section of the Company’s annual report on Form 10-K, quarterly reports on Form 10-Q and other filings with the Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Although the forward-looking statements in this release of financial information are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material or adverse. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Contacts:

Myomo:

ir@myomo.com

Alliance Advisors IR:

Vivian Cervantes

vcervantes@allianceadvisors.com

973-873-7724

(Tables follow)

MYOMO, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Three Months Ended

Six Months Ended

June 30,

2026

2025

2026

2025

Revenue

11,704,565

9,652,234

21,817,853

19,484,048

Cost of revenue

3,262,017

3,600,061

6,473,698

6,822,246

Gross profit

8,442,548

6,052,173

15,344,155

12,661,802

Operating expenses:

Research and development

1,720,463

2,001,331

3,343,623

3,791,355

Selling, clinical and marketing

5,264,090

5,233,885

10,080,849

9,629,689

General and administrative

3,712,481

3,407,277

7,331,221

7,351,332

10,697,034

10,642,493

20,755,693

20,772,376

Loss from operations

(2,254,486

)

(4,590,320

)

(5,411,538

)

(8,110,574

)

Other expense (income), net

Interest expense (income), net

535,744

(106,549

)

1,040,440

(298,540

)

Change in fair value of derivative liabilities

1,199,726

—

360,662

—

1,735,470

(106,549

)

1,401,102

(298,540

)

Loss before income taxes

(3,989,956

)

(4,483,771

)

(6,812,640

)

(7,812,034

)

Income tax expense

31,404

148,201

218,119

284,996

Net loss

(4,021,360

)

(4,631,972

)

(7,030,759

)

(8,097,030

)

Weighted average number of common shares outstanding:

Basic and diluted

42,697,319

41,582,737

42,484,409

41,518,959

Net loss per share attributable to common stockholders

Basic and diluted

(0.09

)

(0.11

)

(0.17

)

(0.20

)

MYOMO, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

June 30,

December 31,

2026

2025

(unaudited)

ASSETS

Current Assets:

Cash and cash equivalents

11,219,217

14,132,027

Short-term investments

2,233,141

4,261,782

Accounts receivable, net

4,945,509

4,096,327

Inventories

3,169,372

3,123,089

Prepaid expenses and other current assets

2,958,442

1,943,860

Total Current Assets

24,525,681

27,557,085

Restricted cash

575,000

Operating lease assets with right of use

6,514,020

6,679,349

Equipment, net

1,986,836

2,212,901

Software development costs, net

1,721,532

1,590,864

Other assets

19,185

21,374

Total Assets

35,342,254

38,636,573

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:

Accounts payable and accrued expenses

7,515,613

5,819,767

Current operating lease liability

730,824

494,662

Income taxes payable

586,644

813,260

Deferred revenue

202,580

218,222

Warrant derivative liability

1,127,498

999,418

Current portion long term debt, net of discount of $73,871

446,962

—

Total Current Liabilities

10,610,121

8,345,329

Non-current operating and financing lease liability

7,370,509

7,665,622

Long-term debt, net of discount of $2,437,757

11,532,254

11,222,155

Total Liabilities

29,512,884

27,233,106

Commitments and Contingencies

—

Stockholders’ Equity:

Preferred stock

—

Common stock

3,953

3,847

Additional paid-in capital

131,326,086

129,929,989

Accumulated other comprehensive income

224,976

164,517

Accumulated deficit

(125,719,181

)

(118,688,422

)

Treasury stock, at cost

(6,464

)

(6,464

)

Total Stockholders’ Equity

5,829,370

11,403,467

Total Liabilities and Stockholders’ Equity

35,342,254

38,636,573

MYOMO, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Six Months Ended June 30,

2026

2025

CASH FLOWS FROM OPERATING ACTIVITIES

Net loss

(7,030,759

)

(8,097,030

)

Adjustments to reconcile net loss to net cash used in operations:

Depreciation and amortization

676,129

349,240

Stock-based compensation

1,639,913

935,093

Accretion of discount on short-term investments

(73,484

)

(23,383

)

Bad debt expense

—

51,643

Amortization of right-of-use assets

362,699

526,600

Amortization of deferred offering cost

524,479

60,045

Change in fair value of derivative liabilities

360,662

—

Other non-cash charges

96,612

(91,984

)

Changes in operating assets and liabilities:

Accounts receivable

(1,065,154

)

(2,975,272

)

Inventories

174,977

(1,204,740

)

Prepaid expenses and other current assets

(1,032,389

)

(615,940

)

Other assets

—

(130,801

)

Accounts payable and accrued expenses

1,703,910

(531,182

)

Operating lease liabilities

(256,321

)

140,536

Deferred revenue

(15,642

)

25,666

Income taxes payable

(207,400

)

(144,392

)

Tenent improvement allowance

—

183,726

Net cash used in operating activities

(4,141,768

)

(11,542,175

)

CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES

1,528,080

(2,653,446

)

CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES

(243,709

)

3,963,494

Effect of foreign exchange rate changes on cash

(55,413

)

100,186

Net change in cash, cash equivalents and restricted cash

(2,912,810

)

(10,131,941

)

Cash, cash equivalents and restricted cash, beginning of period

14,707,027

24,747,373

Cash, cash equivalents and restricted cash, end of period

11,794,217

14,615,432

MYOMO, INC.

RECONCILIATION OF GAAP NET LOSS TO ADJUSTED EBITDA

(unaudited)

For the Three Months

Ended June 30,

For the Six Months

Ended June 30,

2026

2025

2026

2025

GAAP net loss

(4,021,360

)

(4,631,972

)

(7,030,759

)

(8,097,030

)

Adjustments to reconcile to Adjusted EBITDA:

Interest expense (income), net

535,744

(106,549

)

1,040,440

(298,540

)

Depreciation expense

384,539

190,798

676,129

349,240

Stock-based compensation

1,042,665

394,889

1,639,913

935,093

Change in fair value of derivative liabilities

1,199,726

—

360,662

—

Income tax expense

31,404

148,201

218,119

284,996

Adjusted EBITDA

(827,282

)

(4,004,633

)

(3,095,496

)

(6,826,241

)

# # #

GRAPHIC

Filename: img133186882_0.gif · Sequence: 3

Binary file (4378 bytes)

Download img133186882_0.gif

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.1

Document And Entity Information

Aug. 05, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 05, 2026

Entity Registrant Name

Myomo, Inc.

Entity Central Index Key

0001369290

Entity Emerging Growth Company

false

Entity File Number

001-38109

Entity Incorporation, State or Country Code

Entity Tax Identification Number

47-0944526

Entity Address, Address Line One

45 Blue Sky Dr.

Entity Address, Address Line Two

Suite 101

Entity Address, City or Town

Burlington

Entity Address, State or Province

Entity Address, Postal Zip Code

01803

City Area Code

(617)

Local Phone Number

996-9058

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.0001 par value per share

Trading Symbol

MYO

Security Exchange Name

NYSEAMER

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration